¶ 血液类长寿干预措施
血液类干预措施代表了再生医学领域一个充满希望的前沿，通过血浆操作、细胞年轻化和去除与年龄相关的血液因子来靶向衰老。这些方法包括治疗性血浆置换、富血小板血浆 (PRP) 疗法以及实验性的年轻血液输注。新出现的证据表明，这些干预措施通过共同的机制发挥作用，包括减少细胞衰老、调节炎症通路和优化生长因子。
注意：异体共生（Parabiosis）和“年轻血液”输注属于历史性/实验性概念。它们在当今对患者来说并不实用或不可操作，仅属于研究实践，不应作为疗法来追求。
¶ 概述与基本原理
血液是人体的通讯高速公路，携带着激素、生长因子、炎症分子和细胞碎片，这些物质直接影响细胞衰老和衰老过程。[1][2]
随着年龄的增长，血液中会积累有害物质，包括促炎细胞因子、衰老相关分泌表型 (SASP) 因子以及毒性代谢物，这些物质通过炎性衰老 (inflammaging) 机制加速细胞衰老和器官功能障碍。[3][4]
在小鼠中进行的异体共生实验表明，年轻血液可以使衰老的器官恢复活力，而衰老血液则会加速年轻动物的衰老，这为血液类长寿干预措施提供了基本原理。[5][6]
最近的研究已经确定了血液中特定由年龄引起的系统性分子过剩会驱动衰老，这表明靶向清除或置换策略可以恢复年轻时的功能。[7][8]
¶ 血液类干预措施的类型
治疗性血浆置换 (TPE) 涉及去除老化的血浆并用白蛋白或生理盐水溶液进行替换，在保留有益细胞成分的同时，有效稀释与年龄相关的有害因子。[9][10]
富血小板血浆 (PRP) 疗法浓缩自体血小板，将高浓度的生长因子和抗衰老蛋白直接输送到靶组织。[11][12]
年轻血液输注或异时异体共生（heterochronic parabiosis）涉及将年轻血浆直接转移给老年个体，尽管这种方法在很大程度上仍处于实验阶段且存在争议。[13][14]
¶ 血液成分分离技术 (Apheresis Technologies)
血液成分分离技术 (Apheresis technologies) 涉及选择性地去除特定的血液成分，同时将剩余部分输回患者体内。在长寿应用中，这些方法侧重于减少与年龄相关的有害因子，同时保留有益成分。
¶ 血液成分分离的类型
- 治疗性血浆置换 (Therapeutic plasma exchange, TPE)：去除并替换血浆
- 选择性分离 (Selective apheresis)：靶向特定的有害因子
- 细胞分离 (Cellular apheresis)：去除特定的细胞类型
- 脂蛋白分离 (Lipoprotein apheresis)：去除胆固醇和脂质
¶ 作用机制
血液成分分离可能通过以下方式促进长寿：
- 去除衰老细胞因子
- 消除炎症细胞因子
- 减少有害代谢物
- 恢复有益的血浆成分
- 免疫系统调节
¶ 临床应用
当前和探索性的用途包括：
- 用于长寿的治疗性血浆置换
- 选择性去除衰老因子
- 与其他疗法结合使用
- 研究应用
¶ 技术发展
新兴技术旨在实现：
- 更具选择性的因子去除
- 改善安全性
- 缩短操作时间
- 提高患者舒适度
- 降低成本
¶ 边缘与历史概念
¶ 异体共生（历史研究模型）
通过手术将两只动物的循环系统连接起来，证明了循环因子会影响组织衰老和再生。异体共生为现代基于血液的方法提供了理论基础，但它不是一种临床疗法，也没有直接的人类应用。
¶ “年轻血液”输注（实验性，不推荐）
受异体共生研究结果的启发，将年轻捐献者的血浆输注给年长接受者，但在人类中尚未显示出经过证实的抗衰老益处。由于证据不足且存在潜在风险，美国监管机构建议不要在临床试验之外进行这种做法。[15]
新兴方法包括靶向去除特定的衰老因子、细胞外囊泡疗法以及避免使用供体血液的工程化血液因子替代疗法。[16][17]
¶ 共同机制
所有基于血液的干预措施都靶向炎性衰老——这是由积累的损伤和衰老细胞分泌物驱动的衰老特征性慢性低度炎症。[18][19]
这些方法调节生长因子信号通路，包括胰岛素样生长因子（IGF）、血管内皮生长因子（VEGF）和成纤维细胞生长因子，它们调节细胞生长、血管生成和组织修复，这些在再生医学中至关重要。[20][21]
血液干预通过去除 SASP 因子来应对细胞衰老，同时可能传递促进细胞修复和更新的促再生信号。[22][23]
共同机制包括恢复线粒体功能、改善干细胞活性，以及重新平衡随年龄增长而失调的免疫系统反应，这可能利用了再生医学的原理。[24][25]
¶ 比较证据
治疗性血浆置换显示出最强的临床证据，最近的研究表明其可使生物学年龄降低 2.6 岁，并在多个表观遗传衰老时钟上均有改善。[26][27]
PRP 疗法的结果喜忧参半，在面部年轻化等美容应用中具有中等疗效，但对于全身抗衰老作用的证据有限。[28][29]
在啮齿动物中进行的年轻血液输注研究一致显示出寿命延长和器官年轻化，但人类临床证据仍然有限，且安全隐患依然存在。[30][31]
血浆稀释方法表明，去除有害因子可能比添加有益因子更重要，简单的白蛋白替代疗法就显示出了年轻化效果。[32][33]
¶ 安全性考量
基于血液的干预措施带有固有的风险，包括感染传播、免疫反应和心血管并发症，这些都需要仔细的医疗监督。[34][35]
大多数方法的长期安全性数据有限，特别是在重复治疗和可能破坏正常生理过程方面。[36][37]
围绕未经证实的抗衰老应用存在监管担忧，FDA 已针对缺乏严格安全性测试的年轻血浆疗法发出警告。[15:1][38]
所有基于血液的干预措施都面临标准化的挑战，在方案、制备方法和质量控制措施方面的显著差异会影响其安全性和疗效。[39][40]
¶ 未来发展方向
研究重点在于识别特定的有益和有害血液因子，以实现靶向干预，而无需进行全血或血浆移植。[41][42]
包括人造血液替代品和靶向抗衰老（senolytic）药物在内的合成与工程化方法，可能为基于生物血液的疗法提供更安全的替代方案。[43][44]
利用个体生物标志物谱和多组学分析的个性化血液干预措施，可以优化治疗方案并改善疗效。[45][46]
将基于血液的干预措施与热量限制、运动和药物干预等其他长寿策略相结合的组合方法，展现出产生协同效应的潜力。[47][48]
¶ 参见
¶ 参考文献
Aging insights from heterochronic parabiosis models — https://www.nature.com/articles/s41514-024-00166-0 ↩︎
Molecular mechanisms of aging and anti-aging strategies — https://biosignaling.biomedcentral.com/articles/10.1186/s12964-024-01663-1 ↩︎
Connecting aging biology and inflammation in the omics era — https://www.jci.org/articles/view/158448 ↩︎
Inflammation, epigenetics, and metabolism converge to cell senescence and ageing: the regulation and intervention — https://www.nature.com/articles/s41392-021-00646-9 ↩︎
Can You Reverse Aging With a Transfusion of Young Blood? — https://www.popularmechanics.com/science/health/a61207150/young-blood-transfusions/ ↩︎
Young Blood Rejuvenates Old Bodies: A Call for Reflection when Moving from Mice to Men — https://pmc.ncbi.nlm.nih.gov/articles/PMC5836258/ ↩︎
Multi‐Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single‐Blinded Randomized Placebo‐Controlled Therapeutic Plasma Exchange — https://onlinelibrary.wiley.com/doi/10.1111/acel.70103 ↩︎
Will Revitalizing Old Blood Slow Aging? — https://www.cuimc.columbia.edu/news/will-revitalizing-old-blood-slow-aging ↩︎
Old plasma dilution reduces human biological age: a clinical study — https://pubmed.ncbi.nlm.nih.gov/35999337/ ↩︎
Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial) — https://pmc.ncbi.nlm.nih.gov/articles/PMC12218284/ ↩︎
The Well-Forgotten Old: Platelet-Rich Plasma in Modern Anti-Aging Therapy — https://pmc.ncbi.nlm.nih.gov/articles/PMC11545519/ ↩︎
Anti-Aging Potential of Platelet Rich Plasma (PRP): Evidence from Osteoarthritis (OA) and Applications in Senescence and Inflammaging — https://pmc.ncbi.nlm.nih.gov/articles/PMC10451843/ ↩︎
Rejuvenation of young blood on aging organs: Effects, circulating factors, and mechanisms — https://www.sciencedirect.com/science/article/pii/S2405844024086833 ↩︎
The science of young blood transfusions: can blood rejuvenate? — https://www.drugdiscoverynews.com/young-blood-reverses-aging-in-old-organs-15945 ↩︎
FDA warnings about young plasma therapies — https://www.popularmechanics.com/science/health/a61207150/young-blood-transfusions/ ↩︎ ↩︎
Research progress on blood therapy for anti-aging — https://www.sciencedirect.com/science/article/pii/S2090123225005685 ↩︎
Young Plasma Rejuvenates Blood DNA Methylation Profile, Extends Mean Lifespan, and Improves Physical Appearance in Old Rats — https://pmc.ncbi.nlm.nih.gov/articles/PMC11020299/ ↩︎
Immunosenescence: molecular mechanisms and diseases — https://www.nature.com/articles/s41392-023-01451-2 ↩︎
Cellular Senescence and Ageing: Mechanisms and Interventions — https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2022.866718/full ↩︎
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments — https://www.nature.com/articles/s41392-022-01251-0 ↩︎
Human Aging and Age-Related Diseases: From Underlying Mechanisms to Pro-Longevity Interventions — https://www.aginganddisease.org/EN/10.14336/AD.2024.0280 ↩︎
Targeting Cellular Senescence in Aging and Age-Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies — https://www.aginganddisease.org/EN/10.14336/AD.2024.0206 ↩︎
Aging Hallmarks and Progression and Age-Related Diseases: A Landscape View of Research Advancement — https://pubs.acs.org/doi/10.1021/acschemneuro.3c00531 ↩︎
Senescence and aging: Causes, consequences, and therapeutic avenues — https://rupress.org/jcb/article/217/1/65/39207/Senescence-and-aging-Causes-consequences-and ↩︎
Therapeutic plasma exchange (TPE) and blood products – Implications for longevity and disease — https://www.trasci.com/article/S1473-0502(21)00129-4/fulltext ↩︎
Multi‐Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Therapeutic Plasma Exchange — https://onlinelibrary.wiley.com/doi/10.1111/acel.70103 ↩︎
Young Blood & Longevity: Therapeutic Plasma Exchange (TPE) Treatments — https://www.diamandis.com/blog/young-blood-and-longevity-tpe ↩︎
Use of platelet rich plasma for skin rejuvenation — https://onlinelibrary.wiley.com/doi/10.1111/srt.13714 ↩︎
Platelet-rich Plasma use for facial rejuvenation: a clinical trial and review of current literature — https://pmc.ncbi.nlm.nih.gov/articles/PMC8182581/ ↩︎
Rejuvenation of young blood on aging organs: Effects, circulating factors, and mechanisms — https://pubmed.ncbi.nlm.nih.gov/38994040/ ↩︎
Young blood transfusion - Wikipedia — https://en.wikipedia.org/wiki/Young_blood_transfusion ↩︎
Dr. Dobri Kiprov: The Science Behind Plasma Exchange for Longevity — https://beingpatient.com/dobri-kiprov-plasma-exchange-longevity-science/ ↩︎
Plasma Exchange for Longevity — https://yuniquemedical.com/plasma-exchange-for-longevity/ ↩︎
Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study — https://pmc.ncbi.nlm.nih.gov/articles/PMC10041617/ ↩︎
Platelet-Rich Plasma (PRP) Injections — https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/plateletrich-plasma-prp-treatment ↩︎
Study of Efficacy and Safety of the Plasmapheresis Method — https://clinicaltrials.gov/study/NCT04897113 ↩︎
A systematic review of the safety and effectiveness of platelet-rich plasma (PRP) for skin aging — https://pubmed.ncbi.nlm.nih.gov/31628542/ ↩︎
Young Blood Rejuvenates Old Bodies: A Call for Reflection when Moving from Mice to Men — https://pmc.ncbi.nlm.nih.gov/articles/PMC5836258/ ↩︎
A comprehensive review of platelet-rich plasma for the treatment of dermatologic disorders — https://www.tandfonline.com/doi/full/10.1080/09546634.2022.2142035 ↩︎
Platelet Rich Plasma Injections - Standardization Challenges — https://oxfordnatural.clinic/platelet-rich-plasma/ ↩︎
Research progress on blood therapy for anti-aging - Future Directions — https://www.sciencedirect.com/science/article/pii/S2090123225005685 ↩︎
Will Revitalizing Old Blood Slow Aging? - Future Research — https://www.cuimc.columbia.edu/news/will-revitalizing-old-blood-slow-aging ↩︎
Senolytic and Senomorphic Therapies - Synthetic Approaches — https://www.aginganddisease.org/EN/10.14336/AD.2024.0206 ↩︎
Aging interventions and treatments - Synthetic Biology — https://www.nature.com/articles/s41392-022-01251-0 ↩︎
Multi‐Omics Analysis for Personalized Blood-Based Interventions — https://onlinelibrary.wiley.com/doi/10.1111/acel.70103 ↩︎
Personalized Anti-Aging Strategies — https://biosignaling.biomedcentral.com/articles/10.1186/s12964-024-01663-1 ↩︎
Pro-Longevity Interventions - Combination Approaches — https://www.aginganddisease.org/EN/10.14336/AD.2024.0280 ↩︎
Integrated aging interventions targeting multiple pathways — https://www.nature.com/articles/s41392-021-00646-9 ↩︎